Precision Radiation Oncology最新文献_第2页

Editorial: Innovations, advances, and challenges in precision radiation oncology physics 社论：精准放射肿瘤物理学的创新、进步与挑战

Precision Radiation Oncology Pub Date : 2023-12-06 DOI: 10.1002/pro6.1216

Fada Guan, L. Bronk, Jinbo Yue, R. Mohan, Zhe Chen

引用次数: 0

Red shell‐ high risk normal tissue in stereotactic radiosurgery 红色外壳--立体定向放射手术中的高风险正常组织

Precision Radiation Oncology Pub Date : 2023-12-01 DOI: 10.1002/pro6.1218

Jun Yang, W. Qi, Lei Wang, Q. Lu, Liangfu Han, Brian Wang, W. Yan

引用次数: 0

Dual‐Energy CT in Breast Cancer: Current Applications and Future Outlooks 双能量 CT 在乳腺癌中的应用：当前应用与未来展望

Precision Radiation Oncology Pub Date : 2023-12-01 DOI: 10.1002/pro6.1213

Shaolan Guo, Tianye Liu, Guobin Qu, Jian Xu, Qingzeng Liu, Qian Zhao, Zhao Bi, Wanhu Li, Jian Zhu

引用次数: 0

Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced rectal injury 预防和治疗放射性直肠损伤的中国临床实践指南

Precision Radiation Oncology Pub Date : 2023-12-01 DOI: 10.1002/pro6.1217

Hui Zhang, Zhen Zhang, Shuanghu Yuan

引用次数: 0

Comparison of Rapid Arc and Intensity Modulated Radiotherapy in a True Beam Linear Accelerator for 6 MV: Application of AAPM TG‐119 tests in treatment planning and quality assurance 在 6 MV 真光束直线加速器中比较快速弧形放疗和调强放疗：AAPM TG-119 测试在治疗计划和质量保证中的应用

Precision Radiation Oncology Pub Date : 2023-11-29 DOI: 10.1002/pro6.1212

S. Roy, B. Sarkar, Anirudh Pradhan

引用次数: 0

Blockchain + Radiotherapy: The Scenarios of the 5G‐Enabled Smart Radiotherapy Era 区块链+放疗：5G 智能放疗时代的应用场景

Precision Radiation Oncology Pub Date : 2023-11-29 DOI: 10.1002/pro6.1211

Jian Zhu, Jinming Yu

引用次数: 0

Chinese Clinical Practice Guidelines for the Prevention and Treatment of Radiation‐induced Dermatitis 中国放射性皮炎防治临床实践指南

Precision Radiation Oncology Pub Date : 2023-09-20 DOI: 10.1002/pro6.1210

Ming Fan, Mei Feng, Shuanghu Yuan

{"title":"Chinese Clinical Practice Guidelines for the Prevention and Treatment of Radiation‐induced Dermatitis","authors":"Ming Fan, Mei Feng, Shuanghu Yuan","doi":"10.1002/pro6.1210","DOIUrl":"https://doi.org/10.1002/pro6.1210","url":null,"abstract":"Abstract Acute radiation‐induced esophagitis is a common complication of radiotherapy for esophageal, lung, and other malignancies. Therefore, understanding the diagnosis, grading, risk factors, prevention, and treatment of radiation‐induced esophagitis is essential. Currently, there are few consensuses and guidelines on radiation‐induced esophagitis worldwide, mainly the American College of Gastroenterology (ACG) clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE) and the Digestive Endoscopy Society of Chinese Medical Association's “Guidelines for the Diagnosis and Treatment of Reflux Esophagitis.” However, no consensus or guidelines specifically addressing radiation‐induced esophagitis have been established. Efforts have been made to organize experts to draft Chinese consensus or guidelines, but the recommendations in these guidelines also vary owing to differences in expert backgrounds. The clinical practice guidelines presented herein were developed for the first time with the joint participation of Chinese radiotherapy experts. Drugs and methods with clinical significance were selected by reviewing and summarizing the prevention and treatment of radiation‐induced esophagitis and combining them with China's national conditions. After multiple rounds of discussion and revision, clinical practice guidelines were established in line with the needs of Chinese clinicians, providing useful clinical guidance for the prevention and treatment of radiation‐induced esophagitis.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136307120","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition) 聚乙二醇化重组人粒细胞集落刺激因子在同步放化疗中的应用中国专家共识(2023版)

Precision Radiation Oncology Pub Date : 2023-09-01 DOI: 10.1002/pro6.1201

Jun Wang, Baosheng Li

{"title":"Chinese expert consensus on the application of pegylated recombinant human granulocyte colony‐stimulating factor during concurrent chemoradiotherapy (2023 edition)","authors":"Jun Wang, Baosheng Li","doi":"10.1002/pro6.1201","DOIUrl":"https://doi.org/10.1002/pro6.1201","url":null,"abstract":"Neutropenia is the most common hematological toxicity of concurrent chemoradiotherapy (CCRT), and leads to subsequent treatment delays and/or dose reductions. Neutropenia often advances to febrile neutropenia and serious infections, which can affect the prognosis and safety of patients. The reasonable prevention and management of neutropenia is vital for patients with malignancies undergoing CCRT. Pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF), a long‐acting recombinant human granulocyte colony‐stimulating factor, can prevent and treat neutropenia in more convenient clinical settings. Based on relevant guidelines and the most recent clinical data, the Chinese Association for Therapeutic Radiation Oncologists, China Society for Radiation Oncology, and Chinese Association of Radiation Therapy have evaluated the safety and efficacy of PEG‐rhG‐CSF during CCRT, clearly defined the clinical pathway and route of administration for the prevention and treatment of neutropenia, and formed a Chinese expert consensus on PEG‐rhG‐CSF application during CCRT, with the goal of promoting the reasonable clinical use of this treatment.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45625894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical outcomes and recurrence patterns of high‐intermediate‐risk and high‐risk early‐stage endometrial cancer treated with postoperative intracavitary brachytherapy 术后腔内近距离放射治疗高-中危和高危早期子宫内膜癌的临床结果和复发模式

Precision Radiation Oncology Pub Date : 2023-09-01 DOI: 10.1002/pro6.1209

Zihan Yan, Kang Ren, Wenhui Wang, Ke Hu, Xiaorong Hou, Fuquan Zhang

{"title":"Clinical outcomes and recurrence patterns of high‐intermediate‐risk and high‐risk early‐stage endometrial cancer treated with postoperative intracavitary brachytherapy","authors":"Zihan Yan, Kang Ren, Wenhui Wang, Ke Hu, Xiaorong Hou, Fuquan Zhang","doi":"10.1002/pro6.1209","DOIUrl":"https://doi.org/10.1002/pro6.1209","url":null,"abstract":"Abstract Objective To investigate the clinical outcomes and recurrence patterns of high‐intermediate‐risk (HIR)‐ and high‐risk (HR) early‐stage endometrial cancer (EC) treated with postoperative intracavitary brachytherapy alone. Methods We included 152 patients with International Federation of Gynecology and Obstetrics (FIGO) stage I‐II endometrial cancer with HIR and HR factors who received vaginal brachytherapy alone after surgery in our center between April 2008 and December 2017. The irradiation area was the top and upper halves of the vagina. The reference point was defined as 0.5 cm below the vaginal mucosa. The radiation dose was 25–30 Gy 5–6 times. The Kaplan–Meier method was used to calculate the survival rate; differences were assessed using the log‐rank test, and univariate and multivariate prognostic analyses were performed using the Cox regression model. Result The median follow‐up was 49.2 months (range 3–132 months). The 5‐year overall survival (OS), disease‐free survival (DFS), locoregional failure‐free survival time (LRFS), and distant metastasis‐free survival (DMFS) rates were 93.2%, 83.4%, 87.9%, and 86.6%, respectively. Treatment failure occurred in 18 patients, locoregional recurrence in 11, and distant metastasis in 14 (four with locoregional recurrence). Distant metastasis is the main recurrence pattern in patients at HIR and HR. Univariate and multivariate analyses revealed that age was an independent prognostic factor for OS, DFS, DMFS, and LRFS. Conclusion The main recurrence pattern after adjuvant vaginal brachytherapy alone was distant metastasis in patients with HIR and HR early‐stage EC. Age at onset was an independent prognostic factor for survival. Vaginal brachytherapy alone is an acceptable treatment option for patients with HIR and HR early‐stage endometrial cancer.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135349568","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced dermatitis 中国临床实践指南预防和治疗放射性皮炎

Precision Radiation Oncology Pub Date : 2023-09-01 DOI: 10.1002/pro6.1208

Ming Fan, Mei Feng, Shuanghu Yuan

{"title":"Chinese clinical practice guidelines for the prevention and treatment of radiation‐induced dermatitis","authors":"Ming Fan, Mei Feng, Shuanghu Yuan","doi":"10.1002/pro6.1208","DOIUrl":"https://doi.org/10.1002/pro6.1208","url":null,"abstract":"Abstract Radiation‐induced dermatitis is one of the most prevalent complications in patients undergoing cancer radiotherapy and poses a significant challenge to cancer therapy. The symptoms include erythema, dry desquamation, and moist desquamation, which are frequently observed in patients with breast, head and neck, anal, and vulvar cancers. Early skin reactions typically manifest within 2–4 weeks following the initiation of radiotherapy. In severe cases, acute dermatitis can cause radiotherapy interruptions, prolong treatment time, and ultimately affect patient outcomes and quality of life. Currently, there are numerous guidelines on radiation dermatitis, including the Multinational Association of Supportive Care in Cancer (MASCC), British Columbia Cancer Agency (BCCA), Oncology Nursing Society (ONS), and UK Society of Radiographers (SCoR) guidelines. In China, dermatology experts have drafted a consensus. However, due to the differing backgrounds of experts, recommendations among guidelines vary. These guidelines were first developed by Chinese radiation oncologists. The evidence‐based guideline in this paper fully considers and adopts China's national conditions; hence, it can be easily applied in daily practice.","PeriodicalId":32406,"journal":{"name":"Precision Radiation Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135255623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0